Isolated antigen-binding proteins and uses thereof

JP2024541053AActive Publication Date: 2024-11-06LONGBIO PHARM (SUZHOU) CO LTD
View PDF 9 Cites 0 Cited by

Patent Information

Application Number
JP2024525974
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Filing Date
2021-10-29
Publication Date
2024-11-06
Estimated Expiration
2041-10-29

AI Technical Summary

Technical Problem

Allergic diseases, including allergic rhinitis, asthma, and atopic dermatitis, are prevalent and affect a significant portion of the population, with IgE-mediated hypersensitivity reactions being a major contributor. Current treatments lack effective methods to control IgE levels and manage allergic responses.

Method used

Development of antigen-binding proteins with enhanced affinity for the neonatal FcRn receptor, providing stability and a longer half-life, which can suppress the binding of IgE to its receptors FcεRIa and FcεRII, thereby reducing allergic responses.

Benefits of technology

The antigen-binding proteins effectively inhibit IgE receptor binding, offering a potential therapeutic approach to alleviate IgE-related diseases by extending the administration cycle and improving drug discoverability and industrial production stability.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024541053000002
    Figure 2024541053000002
  • Figure 2024541053000003
    Figure 2024541053000003
  • Figure 2024541053000004
    Figure 2024541053000004
Patent Text Reader

Abstract

The present application relates to an antigen-binding protein comprising at least one CDR of a heavy chain variable region comprising the amino acid sequence shown in any one of SEQ ID NOs: 73 and 74, and at least one CDR of a light chain variable region comprising the amino acid sequence shown in any one of SEQ ID NOs: 75 and 76.
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • Human monoclonal antibody against IgE, preparation method and purpose thereof

    CN102167745A

  • Binding element for IgE molecule

    JP2010519194A

  • Humanized anti-IgE antibodies that cross-link with CD23 on B lymphocytes but do not sensitize mast cells.

    JP2017518320A

  • asct2-specific binding molecules and uses thereof

    JP2018535674A

  • PCSK9 antibodies, antigen-binding fragments thereof and pharmaceutical uses

    JP2019509254A